- Immutep (IMM) has released further interim data from its Phase II TACTI-002 Study in patients with lung, head, and neck cancers
- The study evaluates a combined treatment using Immutep’s eftilagimod alpha (efti) with MSD’s KEYTRUDA (also known as pembrolizumab) candidate
- Efti is a soluble LAG-3 fusion protein and antigen-presenting cell activator, while pembrolizumab is a PD-1 inhibitor
- So far, results show the combined treatment has therapeutic benefits and a good safety profile, standing it in good stead for further clinical development
- Immutep will enrol up to 25 extra patients in the study and expects to report more mature trial data in the first half of 2021
- Shares have been trading 1.7 per cent lower at 29 cents
